We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.80 | 8.44% | 48.80 | 48.00 | 49.00 | 49.00 | 45.00 | 45.00 | 5,721,464 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.51 | 137.55M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/10/2018 07:08 | So as the CEO intimated last week we have a licensing deal on the diagnostics side of the business. No revenues until next year at the earliest but it validates the usefulness of the products. I guess there will be more deals to follow.... | nobbygnome | |
08/10/2018 15:11 | Thanks Timbo | 1i1i1i | |
08/10/2018 12:18 | Slides and video from the recent TPI investor evening are here: Good questions at the end 😉 | timbo003 | |
05/10/2018 08:25 | I was at the Proactive investor meeting last night and was impressed by the presentation. I was already a shareholder as a result of the recent fund raising but hadn't really looked into the technology as much as I should have done. There are various aspects of the affimer platform which are advantageous. For example the fact that the structure gets around the antibody IP mean that this technology can be used in a variety of beneficial ways commercially. In addition the fact that the reagents used in the diagnostic area are plant based means it is distinctly separate from the therapeutic products. Plus the company is clearly focused on getting deals in the short term. The CEO said a diagnostics deal is imminent and others will follow. And the company is funded into 2020 and that doesn't include any deals in the interim. The key time will be when they get to the first in human studies which will be Q1 next year with the PDL1-LAGS bispecific. Yes I have bought some more this morning via spreadbet.... Nobby | nobbygnome | |
02/10/2018 14:28 | Yep Academic CEO's don't you just love them! | lantanatony | |
02/10/2018 14:18 | Unbelievable turnover more or less the same but losses have gone up to £8.83 million. This is over three times the turnover. How many more new share issues can they have? | poacher45 | |
25/9/2018 12:14 | results next week ... too much to hope for update on deals or collaborations | the drewster | |
25/9/2018 11:46 | Looks like it's heading back upwards. All I can get online is 15k at 25.68p | dave4545 | |
24/9/2018 21:52 | Well in theory you shouldn’t get more than is in public domain other than sight of whites of their eyes! | bscuit | |
24/9/2018 17:18 | Well,No need to go to this one as it will be the same old stuff! | lantanatony | |
24/9/2018 12:00 | I was one of 3 PIs that attended the last dedicated investor event at fincap. | the drewster | |
24/9/2018 11:15 | I will be there! | nobbygnome | |
24/9/2018 10:58 | Avacta will be presenting to investors at the upcoming Proactive One2One Forum on 4th October in London. Details here: | aim_trader | |
11/9/2018 11:55 | 83k sold for 24.75p when 26p bid ! Nice profit for the mm who took that | dave4545 | |
10/9/2018 08:12 | 27.8p full offer paid for 20k Strange as a 20k dummy buy here is 27.25p online | dave4545 | |
07/9/2018 23:02 | I have just seen Alistair Smith on LSE interview. It's the same old jam tomorrow stuff. In fact it is a disgrace saying that shareholders should only consider Avacta as a new company! Because it's only had the Affimer technology for a few years. Well what about the long-term investors that were sold a pup. This company is not worthy. | lantanatony | |
05/9/2018 21:00 | Company for sale. Great potential. Other management needed who can add the value and steal the company!! | escapetohome | |
05/9/2018 20:58 | Yep Hardman just a rehash of all gone before ! It seem Avacta have nothing more to say. It seems just a conduit to pay the Directors. And I forgot to mention the Brokers and other professionals. | lantanatony | |
05/9/2018 17:14 | Hardman note is Hardly informative | toffeeman | |
05/9/2018 12:26 | Hardman & Co. note out today on Avacta. | mortimer7 | |
05/9/2018 00:26 | Look at the Novartis news overnight Each treatment costs $ 475,000 | hampton58 | |
03/9/2018 23:19 | The planet that you are on would help... | ffp |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions